CD28 and acute lymphoblastic leukemia: Chen et al. found that third-generation anti-CD5 CAR Transduced NK-92 cells with CD28 and 4-1BB costimulatory domains have potent in vitro cytotoxicity against primary patient-derived -cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoma, and Sezary cells, as well as enhanced survival in a Jurkat lymphoma xenograft mouse model [72].